Loading
The six-year OlympiA update: the year of olaparib still cut relapse by 35 percent and death by 28 percent, six-year survival was 87.5 versus 83.2 percent, there were fewer new BRCA-related breast and ovarian cancers, and no excess of leukaemia.
Garber, Cameron, Campbell, Yothers and colleagues report the third pre-specified interim analysis of OlympiA (NCT02032823) at a median follow-up of 6.1 years, with descriptive analyses of invasive disease-free survival, distant disease-free survival and overall survival. Olaparib benefit was maintained: invasive disease-free survival hazard ratio 0.65 (95 percent confidence interval 0.53 to 0.78), distant disease-free survival 0.65 (0.53 to 0.81) and overall survival 0.72 (0.56 to 0.93); six-year overall survival was 87.5 versus 83.2 percent (difference 4.4 percentage points, 95 percent CI 0.9 to 6.7). Benefit was consistent across key subgroups including high-risk hormone receptor-positive disease. There were fewer BRCA-associated new breast and ovarian or fallopian tube cancers and no increase in adverse events of special interest (6.3 versus 9.3 percent), including myelodysplastic syndrome or acute myeloid leukaemia (0.4 versus 0.7 percent).
Answers the two questions that hung over adjuvant olaparib, durability and late leukaemia, in its favour; the remaining question is whether carriers who also received pembrolizumab or capecitabine, whom the trial did not study, get the same benefit.
Shares A UK audit of trial access and germline testing uptake in triple-negative breast cancer, OlympiA, PARP inhibitors, Olaparib and the tag tnbc-evidence.
Shares OlympiA, KEYNOTE-522, Annals of Oncology, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares A UK audit of trial access and germline testing uptake in triple-negative breast cancer, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares KEYNOTE-522, Annals of Oncology, Germline (hereditary) testing, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Annals of Oncology, Overall survival (OS), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, AstraZeneca and the tag tnbc-evidence.
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares A UK audit of trial access and germline testing uptake in triple-negative breast cancer, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.